Labial adhesion is a common condition found in girls before puberty. All the patients (n = 15) in this series were diagnosed clinically, and routine blood and urine examinations were normal. Mometasone cream was applied topically over the labial adhesions with a positive therapeutic response within 3–8 weeks of treatment. Recurrences of adhesions were found only in two patients who discontinued the treatment after recovery, and repetition of the treatment for 8 weeks solved the issue. Nonsignificant side effects were seen only in two patients. Hence, it can be concluded that mometasone cream is an effective method of treatment for labial adhesions.

An acquired condition called labial synechia results from inflammation that encourages fusions between the labia minora. Estrogen cream has been used in the majority of trials to treat individuals with labial synechia, but recurrences are common with this treatment. The purpose is to evaluate the effectiveness of mometasone cream used topically in treating individuals with recurrent labial synechia. Patients with recurrent labial synechia (n = 5) ranged in age from 2 years and 3 months to 3 years and 9 months. Mometasone cream was applied topically over the adhesions twice a day. Two cases were healed after 5 weeks of mometasone cream exposure, two needed 6 weeks, and one needed 7 weeks. Side effects were essentially imperceptible. Therefore, it can be concluded that mometasone cream is a successful treatment for recurrent labial synechia.

Monkeypox is a viral zoonotic disease that mostly affects tropical rainforest regions of Central and West Africa, with infrequent exportations to other parts of the world. The cause of monkeypox is the monkeypox virus, a species of the Orthopoxvirus genus in the family Poxviridae. Monkeypox often has symptoms that last between 2 and 4 weeks and is a self-limiting condition. Severe cases could exist. Monkeypox can be spread to humans by close contact with infected animals or people, as well as through coming into contact with contaminated materials. By coming into intimate contact with lesions, bodily fluids, respiratory droplets, and contaminated things like bedding, the monkeypox virus can be transferred from one person to another. The smallpox immunizations used in the smallpox eradication campaign also provided immunity to that illness. One of the more recent vaccinations, which is now accessible, is approved for the protection of monkeypox. Hexadecyloxypropyl-cidofovir (CDV) has superior oral bioavailability, less toxicity, and improved cellular penetration compared to CDV, administered intravenously. The European Medicines Agency authorized tecovirimat, an antiviral medicine developed to treat smallpox, to treat monkeypox in 2022 on the basis of data from both animal and human testing. It is still not readily accessible.